Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

AB

Ab Science (AB)

Ab Science

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:EU:AB

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
10/28/2024	12:47PM	GlobeNewswire Inc.	AB Science receives notice of allowance for European patent covering masitinib until 2040 in the treatment of sickle cell disease	EU:AB	Ab Science
10/17/2024	1:28PM	GlobeNewswire Inc.	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS	EU:AB	Ab Science
10/10/2024	2:27AM	GlobeNewswire Inc.	AB Science: Revenues for the first half of 2024 and update on AB Science’s activities	EU:AB	Ab Science
09/30/2024	12:33PM	GlobeNewswire Inc.	AB Science announces a slight delay in the publication of its 2024 half-year financial report	EU:AB	Ab Science
09/26/2024	2:28AM	GlobeNewswire Inc.	AB Science provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement	EU:AB	Ab Science
09/23/2024	11:51AM	GlobeNewswire Inc.	AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024	EU:AB	Ab Science
07/08/2024	1:56AM	GlobeNewswire Inc.	AB Science annonce des résultats positifs de son étude de Phase 2 évaluant le masitinib dans la Covid-19	EU:AB	Ab Science
07/08/2024	1:56AM	GlobeNewswire Inc.	AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19	EU:AB	Ab Science
07/08/2024	1:56AM	GlobeNewswire Inc.	AB Science announces positive results of its Phase 2 study evaluating masitinib in Covid-19	EU:AB	Ab Science
06/28/2024	6:31AM	GlobeNewswire Inc.	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS	EU:AB	Ab Science
06/28/2024	6:31AM	GlobeNewswire Inc.	AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA	EU:AB	Ab Science
06/28/2024	6:31AM	GlobeNewswire Inc.	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS	EU:AB	Ab Science
06/27/2024	4:15AM	GlobeNewswire Inc.	AB Science - Résultats de l'Assemblée Générale Mixte du 26 juin 2024	EU:AB	Ab Science
05/31/2024	10:30AM	GlobeNewswire Inc.	AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS	EU:AB	Ab Science
05/31/2024	10:30AM	GlobeNewswire Inc.	AB Science fournit un résumé de la conférence virtuelle qui s'est tenue le 30 mai 2024, faisant le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA	EU:AB	Ab Science
05/31/2024	10:30AM	GlobeNewswire Inc.	AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing authorization of masitinib in ALS	EU:AB	Ab Science
05/29/2024	12:02PM	GlobeNewswire Inc.	AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA	EU:AB	Ab Science
05/29/2024	12:02PM	GlobeNewswire Inc.	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS	EU:AB	Ab Science
05/29/2024	12:02PM	GlobeNewswire Inc.	AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS	EU:AB	Ab Science
05/17/2024	11:58AM	GlobeNewswire Inc.	AB Science communique un rectificatif sur les comptes consolidés au 31 décembre 2023	EU:AB	Ab Science
05/15/2024	2:16PM	GlobeNewswire Inc.	AB Science annonce ses résultats financiers annuels arrêtés au 31 décembre 2023 et présente un point sur ses activités	EU:AB	Ab Science
05/15/2024	2:16PM	GlobeNewswire Inc.	AB Science reports its revenues for the year 2023 and provides an update on its activities	EU:AB	Ab Science
05/15/2024	2:16PM	GlobeNewswire Inc.	AB Science reports its revenues for the year 2023 and provides an update on its activities	EU:AB	Ab Science
05/13/2024	12:08PM	GlobeNewswire Inc.	AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036	EU:AB	Ab Science
05/13/2024	12:08PM	GlobeNewswire Inc.	AB Science announces issuance of a European patent for masitinib in the treatment of severe mastocytosis with protection until 2036	EU:AB	Ab Science
05/13/2024	12:08PM	GlobeNewswire Inc.	AB Science annonce la délivrance d’un brevet européen pour le masitinib dans le traitement de la mastocytose sévère avec une protection jusqu’en 2036	EU:AB	Ab Science
05/07/2024	12:05PM	GlobeNewswire Inc.	AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient	EU:AB	Ab Science
05/07/2024	12:05PM	GlobeNewswire Inc.	AB Science:	EU:AB	Ab Science
05/07/2024	12:05PM	GlobeNewswire Inc.	AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient	EU:AB	Ab Science
05/02/2024	1:14PM	GlobeNewswire Inc.	AB Science : The Paris Court of Appeal confirms the acquittal of the CEO of AB Science, Alain Moussy, and reduces the amount of the financial penalty imposed on AB Science	EU:AB	Ab Science

Showing the most relevant articles for your search:EU:AB

1 2 3 4 5 6 7 8 9 10 Next >>

TransCode Therapeutics

KULR Technology

TPT Global Tech (CE)

FuelCell Energy

Fannie Mae (QB)

Bioelectronics (PK)

Moon Equity (PK)

Digital Brand Media and ... (PK)

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions